DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B‐CELL NON‐HODGKIN LYMPHOMA. (12th June 2019) - Viardot, A.